Myelodysplastic Syndromes (MDS): Diagnosis, Risk Stratification, and Evidence-Based Management for the Practicing Hematologist/Oncologist
Introduction and Pathophysiology Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell disorders characterized by: The pathogenesis involves somatic mutations in genes regulating splicing (SF3B1, SRSF2, U2AF1), DNA methylation (DNMT3A, TET2, IDH1/2), chromatin modification (EZH2), transcription (RUNX1), signal transduction (NRAS, KRAS, CBL), and cohesion complex (RAD21, STAG2). These mutations drive genomic instability,…
